From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

J&J Tuberculosis Drug Submitted for FDA New Drug Application Approval

by Global Biodefense Staff
July 4, 2012

Johnson & Johnson’s Janssen Research & Development unit announced Monday that they have filed a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bedaquiline. If approved, the drug would be the first tuberculosis (TB) countermeasure in over 40 years with a new mechanism of action.

The Janssen TB drug targets adenosine triphosphate synthase, which Mycobacterium tuberculosis requires for generating its energy. Bedaquiline is seeking indications as an oral treatment to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.  If approved, bedaquiline would also be the first medication intended for treating the resistant forms of TB.

Despite widespread use of an existing vaccine and the availability of several anti-TB drugs, the disease remains a major global health problem. In 2010, 8.8 million people fell ill with TB and 1.4 million died of the disease, according to the World Health Organization. Of those, an estimated 650,000 were cases of MDR-TB. The prevalence of resistant strains is on the rise, and is especially common in Africa and Asia.

A Phase III clinical trial comparing nine months of medication with bedaquiline in contrast with a placebo in about 600 patients is scheduled to begin at the end of 2012. The study will assess the new shorter treatment length of 9 months as compared the current 18 to 24 months recommended by the World Health Organization (WHO).

The company noted that this first filing in the U.S. will be followed by applications in other countries where TB is prevalent.

From Our Partners
Tags: Tuberculosis

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC